Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eupraxia PharmaceuticalsSTU:X43 -3.51%22 WACC % is 9.53% as of Jul. 14, 2026, which is 29% below its 10-year median of 13.43. GuruFocus rates STU:X43 with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 1,421 Biotechnology companies, Eupraxia Pharmaceuticals ranks worse than 80.3% on this metric.
As of today (2026-07-14), Eupraxia Pharmaceuticals's weighted average cost of capital is 9.53%%. Eupraxia Pharmaceuticals's ROIC % is -3135.89% (calculated using TTM income statement data).
Eupraxia Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.
*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
For a comprehensive WACC calculation, please access the WACC Calculator.
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Eupraxia Pharmaceuticals's weighted average cost of capital is 9.53%%. Eupraxia Pharmaceuticals's ROIC % is -3135.89% (calculated using TTM income statement data).
Eupraxia Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.
*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eupraxia Pharmaceuticals's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eupraxia Pharmaceuticals WACC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's WACC % distribution charts can be found below:
* The bar in red indicates where Eupraxia Pharmaceuticals's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Eupraxia Pharmaceuticals's market capitalization (E) is €367.292 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Eupraxia Pharmaceuticals's latest one-year quarterly average Book Value of Debt (D) is €0.4184 Mil.
a) weight of equity = E / (E + D) = 367.292 / (367.292 + 0.4184) = 0.9989
b) weight of debt = D / (E + D) = 0.4184 / (367.292 + 0.4184) = 0.0011
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 3.5415%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Eupraxia Pharmaceuticals's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 3.5415% + 1 * 6% = 9.5415%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Eupraxia Pharmaceuticals's interest expense (positive number) was €-0 Mil. Its total Book Value of Debt (D) is €0.4184 Mil.
Cost of Debt = -0 / 0.4184 = 0%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0.025 / -38.21 = -0.07%, which is less than 0%. Therefore it's set to 0%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eupraxia Pharmaceuticals (STU:X43) has a WACC % of 9.53% as of Jul. 14, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Eupraxia Pharmaceuticals and its competitors. This is 29% below median its historical median of 13.43. Over the past decade, Eupraxia Pharmaceuticals' WACC % has ranged from 8.79 to 23.02. According to the industry distribution chart, Eupraxia Pharmaceuticals ranks #1141 out of 1421 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Eupraxia Pharmaceuticals' WACC % too high?
Eupraxia Pharmaceuticals' current WACC % of 9.53% is 29% below median its 10-year median of 13.43. Over the past 10 years, this metric has ranged from a low of 8.79 to a high of 23.02. The Biotechnology industry median WACC % is 10.01. Eupraxia Pharmaceuticals' value of 9.53% is 4.8% below this industry median. Based on the distribution chart, Eupraxia Pharmaceuticals ranks #1141 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' WACC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Eupraxia Pharmaceuticals ranks #1141 out of 1421 companies for WACC %. This places Eupraxia Pharmaceuticals in the lower half of its industry. The industry median WACC % is 10.01. Eupraxia Pharmaceuticals' value of 9.53% is 4.8% below this benchmark. Historically, Eupraxia Pharmaceuticals' own WACC % has ranged from 8.79 to 23.02 over the past decade. While the company's 10-year median is 13.43 vs. the industry median of 10.01, Eupraxia Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.01, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eupraxia Pharmaceuticals's current WACC % of 9.53% is 4.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Eupraxia Pharmaceuticals and its competitors. For the Biotechnology industry, the median WACC % is 10.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eupraxia Pharmaceuticals's current WACC % is 9.53%, which is 29% below median its own 10-year median of 13.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (STU:X43) has a current WACC % of 9.53%. The current WACC % is 9.53%, which is 29% below median its 10-year median of 13.43 and 4.8% below the Biotechnology industry median of 10.01. Eupraxia Pharmaceuticals' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (STU:X43), the current WACC % is 9.53% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
22GF Score
Get the complete analysis for STU:X43
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:X43 has been successfully added to your 
